Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($1.54), $0.30 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $46.01 million versus the consensus estimate of $40.89 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.